Annexon Biosciences to Present at the Jefferies London Healthcare Conference
Annexon Biosciences (Nasdaq: ANNX) has announced its participation in the upcoming Jefferies London Healthcare Conference. Douglas Love, president and CEO, will deliver a presentation on Wednesday, November 20, 2024, at 10:30 a.m. GMT. The presentation will be accessible via live webcast in the 'Events & Presentations' section of the company's investor page. A recording will remain available on the Annexon website for 30 days after the event. The company specializes in developing therapies for neuroinflammatory diseases affecting the body, brain, and eye, focusing on upstream C1q.
Annexon Biosciences (Nasdaq: ANNX) ha annunciato la sua partecipazione al prossimo Jefferies London Healthcare Conference. Douglas Love, presidente e CEO, presenterà un intervento mercoledì 20 novembre 2024, alle 10:30 GMT. La presentazione sarà accessibile tramite webcast dal vivo nella sezione 'Eventi e Presentazioni' della pagina per investitori della compagnia. Una registrazione rimarrà disponibile sul sito web di Annexon per 30 giorni dopo l'evento. L'azienda si specializza nello sviluppo di terapie per malattie neuroinfiammatorie che colpiscono il corpo, il cervello e gli occhi, concentrandosi sul C1q a monte.
Annexon Biosciences (Nasdaq: ANNX) ha anunciado su participación en la próxima Jefferies London Healthcare Conference. Douglas Love, presidente y CEO, dará una presentación el miércoles 20 de noviembre de 2024, a las 10:30 a.m. GMT. La presentación estará disponible a través de una retransmisión en vivo en la sección 'Eventos y Presentaciones' de la página de inversores de la compañía. Una grabación permanecerá disponible en el sitio web de Annexon durante 30 días después del evento. La empresa se especializa en el desarrollo de terapias para enfermedades neuroinflamatorias que afectan al cuerpo, cerebro y ojos, centrándose en el C1q ascendente.
Annexon Biosciences (Nasdaq: ANNX)가 다가오는 Jefferies London Healthcare Conference에 참여한다고 발표했습니다. Douglas Love 사장 겸 CEO가 2024년 11월 20일 수요일 오전 10시 30분 GMT에 발표를 진행할 예정입니다. 발표는 회사 투자자 페이지의 '이벤트 및 발표' 섹션에서 생중계로 접속할 수 있습니다. 이벤트 후 30일 동안 Annexon 웹사이트에서 녹화본을 이용할 수 있습니다. 이 회사는 신체, 두뇌 및 눈에 영향을 미치는 신경 염증 질환 치료제 개발에 전문화되어 있으며, 상류 C1q에 중점을 두고 있습니다.
Annexon Biosciences (Nasdaq: ANNX) a annoncé sa participation à la prochaine Jefferies London Healthcare Conference. Douglas Love, président et PDG, fera une présentation le mercredi 20 novembre 2024 à 10h30 GMT. La présentation sera accessible par webcast en direct dans la section 'Événements et Présentations' de la page des investisseurs de l'entreprise. Un enregistrement sera disponible sur le site de Annexon pendant 30 jours après l'événement. L'entreprise se spécialise dans le développement de thérapies pour les maladies neuroinflammatoires affectant le corps, le cerveau et les yeux, en se concentrant sur le C1q en amont.
Annexon Biosciences (Nasdaq: ANNX) hat seine Teilnahme an der bevorstehenden Jefferies London Healthcare Conference angekündigt. Douglas Love, Präsident und CEO, wird am Mittwoch, den 20. November 2024, um 10:30 Uhr GMT eine Präsentation halten. Die Präsentation wird über einen Live-Webcast im Abschnitt 'Veranstaltungen & Präsentationen' der Investoren-Seite des Unternehmens zugänglich sein. Eine Aufzeichnung wird 30 Tage nach der Veranstaltung auf der Annexon Website verfügbar sein. Das Unternehmen spezialisiert sich auf die Entwicklung von Therapien für neuroinflammatorische Krankheiten, die den Körper, das Gehirn und die Augen betreffen, mit einem Schwerpunkt auf dem C1q stromaufwärts.
- None.
- None.
BRISBANE, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company focused on upstream C1q to advance therapies for neuroinflammatory diseases of the body, brain and eye, today announced that Douglas Love, president and chief executive officer, will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 10:30 a.m. GMT.
A live webcast of the event can be accessed under the ‘Events & Presentations’ section on the Investors page at www.annexonbio.com. A replay of the webcast will be archived on the Annexon website for 30 days following the presentation.
About Annexon
Annexon Biosciences (Nasdaq: ANNX) is harnessing neuroinflammation to advance potentially first-in-kind treatments for millions of people living with serious neuroinflammatory diseases of the body, brain and eye. Our novel scientific approach focuses on C1q, the initiating molecule of a potent inflammatory pathway that when misdirected can lead to tissue damage and loss. By targeting C1q, our immunotherapies are designed to stop neuroinflammatory diseases where they start. Our pipeline spans three diverse therapeutic areas – neurodegenerative, ophthalmic and autoimmune diseases – and includes investigational drug candidates designed to address the unmet needs of over 8 million people worldwide. Annexon’s mission is to deliver potentially game-changing therapies to patients so that they can live their best lives. When they thrive, we thrive. To learn more visit annexonbio.com.
Investor Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
Media Contact:
Sheryl Seapy
Real Chemistry
949-903-4750
sseapy@realchemistry.com
FAQ
When is Annexon (ANNX) presenting at the Jefferies London Healthcare Conference 2024?
How can I watch Annexon's (ANNX) presentation at the Jefferies Conference?
How long will Annexon's (ANNX) Jefferies Conference presentation replay be available?
What is Annexon's (ANNX) therapeutic focus?
